eISSN: 3023-6940
  • Home
  • Simultaneous native nephrectomy with renal transplantation: Our experience and a brief literature review
E-SUBMISSION

Original Research

Simultaneous native nephrectomy with renal transplantation: Our experience and a brief literature review


1  University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Department of Urology, Istanbul, Turkey
2 Arnavutköy State Hospital, Department of Urology, Istanbul, Turkey


DOI : 10.33719/yud.2022;17-1-947050
New J Urol. 2022; 17(1):14-21

Abstract

Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH)  is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate


Abstract

Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH)  is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate

Resources